Please login to the form below

Not currently logged in
Email:
Password:

Black triangle monitoring warning to be used across EU

Use of symbol is part of EMA plans to strengthen pharmacovigilance

EMA black triangleAll medicines subject to additional monitoring in Europe will have to carry a black inverted triangle warning in line with new pharmacovigilance rules published by the European Medicines Agency (EMA).

The addition of the symbol - which already used by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) – is part of EMA plans to strengthen drug safety measures across the EU in the wake of such controversies as the continued marketing of Servier's Mediator despite safety concerns.

Medicines that will need to carry the symbol by September 2013 include all drugs that contain a new active substance and all biological medicines authorised by the EMA after January 1, 2011.

All treatments that require additional data after authorisation and medicines subject to restrictions will also need to carry the black triangle by this date.

A full list of affected medicines will be published within the next few months.

The symbol will need to appear on both the summary of product characteristics and package leaflet, and will be accompanied by a statement explaining that the medicine is under additional monitoring, as well as a further explanatory sentence.

In addition, updated product information will encourage patients and healthcare professionals to report adverse reactions, with new label requirements to identify the different ways to report an adverse event, including electronic reporting and the appropriate postal address.

According to the EMA, these changes will “allow easy identification of human medicines that are subject to additional monitoring and to encourage adverse-reaction reporting for all medicines”.

The EMA's pharmacovigilance plans came into force in July 2012, and include the formation of the Pharmacovigilance Risk Assessment Committee (PRAC) to oversee drug safety issues in the EU.

Other plans include the introduction of an automatic urgent procedure for review at EU level and greater transparency for pharma companies that withdraw a medicine from the market.

19th March 2013

From: Regulatory, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

If you needed an organ transplant, would you have one?
Lauren Packer discusses the worsening problem in the UK with an imbalance between the number of organs needed, and the number of those being donated....
Why tugging at our heartstrings is no longer enough to make us open our purses
Charlotte Shyllon (Director and Partner) and Maren Thurow (Senior Account Executive), discuss the highly emotive Make a Child Cry campaign video from Doctors of the World (Médecins du Monde)....
quantify_messages.png
Exploring full potential of e-detailing data
Today’s high quality e-detailing data can create better quality conversations with healthcare professionals and result in improved access and relationships....

Infographics